RCT | Adjuvant temozolomide with or without interferon alfa in patients with newly diagnosed high-grade gliomas

Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial – JAMA Network Open

Commentary: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor

Commentary on Twitter

This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G

— JAMA Network Open (@JAMANetworkOpen) January 27, 2023